NCT07441460 2026-03-02
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
Clinical Trials
9 trialsNCT06975644 2025-05-22
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
Zhejiang Provincial People's Hospital
Phase NA Not yet recruiting
NCT06470633 2024-06-24
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06404463 2024-05-08
QUEEN-Neo
Fudan University
Phase 2 Not yet recruiting
NCT06371807 2024-04-17
KEYPARTNER
Fundacao Champalimaud
Phase 2 Not yet recruiting
NCT05983094 2023-08-09
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05287308 2022-03-31
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
ChineseAMS
Phase NA Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04301739 2020-03-12
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Shanghai Henlius Biotech
Phase 3 Not yet recruiting